Share：
Share this content in WeChat
X
[Chinese][PDF]102682
• Review •
Advances in dynamic contrast-enhanced magnetic resonance imaging in predicting tumor prognosis
WANG Qizheng  CHEN Yongye  ZHANG Enlong  ZHANG Jiahui  LANG Ning  YUAN Huishu 

Cite this article as: Wang QZ, Chen YY, Zhang EL, et al. Advances in dynamic contrast-enhanced magnetic resonance imaging in predicting tumor prognosis. Chin J Magn Reson Imaging, 2019, 10(7): 556-560. DOI:10.12015/issn.1674-8034.2019.07.015.


[Abstract] In recent years, the prognosis of neoplastic diseases has been paid attention to during clinical diagnosis and treatment. At present, there are many advances in the study of prognosis prediction of tumor diseases by multimodal magnetic resonance imaging. Dynamic contrast-enhanced magnetic resonance imaging is a kind of multi-modal magnetic resonance. It can be based on the perfusion and permeation of tumor tissue microvascular system. Through continuous and rapid imaging methods, images before and after injection of contrast agent can be obtained, combined with semi-quantitative and quantitative analysis. From the perspective of microcirculation, the microscopic condition of the lesion is analyzed, and the dynamic data analysis is carried out by quantitative or semi-quantitative methods. The characteristics of the tumor are evaluated from different aspects, and it has been widely used in the prognosis prediction of tumor diseases. In this paper, the research progress of dynamic contrast-enhanced magnetic resonance imaging in the prediction of tumor disease prognosis is reviewed, and its clinical application value is clarified.
[Keywords] neoplasms；microvessels；magnetic resonance imaging；prognosis；survivorship

WANG Qizheng Department of Radiology, Peking University Third Hospital, Beijing 100191, China

CHEN Yongye Department of Radiology, Peking University Third Hospital, Beijing 100191, China

ZHANG Enlong Departmrnt of Radiology, Peking University International Hospital, Beijing 102206, China

ZHANG Jiahui Department of Radiology, Peking University Third Hospital, Beijing 100191, China

LANG Ning* Department of Radiology, Peking University Third Hospital, Beijing 100191, China

YUAN Huishu Department of Radiology, Peking University Third Hospital, Beijing 100191, China

*Corresponding to: Lang N, E-mail: 13501241339@126.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work is part of National Natural Science Foundation of China No. 81701648, 81471634 and Key Clinical Projects of the Peking University Third Hospital No. BYSY2018007
Received  2019-02-02
Accepted  2019-04-08
DOI: 10.12015/issn.1674-8034.2019.07.015
Cite this article as: Wang QZ, Chen YY, Zhang EL, et al. Advances in dynamic contrast-enhanced magnetic resonance imaging in predicting tumor prognosis. Chin J Magn Reson Imaging, 2019, 10(7): 556-560. DOI:10.12015/issn.1674-8034.2019.07.015.

[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]
Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer, 2005, 92(9): 1599-1610.
[3]
Sourbron S. Technical aspects of MR perfusion. Eur J Radiol, 2010, 76(3): 304-313.
[4]
Ingrisch M, Sourbron S. Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer. J Pharmacokinet Pharmacodyn, 2013, 40(3): 281-300.
[5]
Sourbron S. Technical aspects of MR perfusion. Eur J Radiol, 2010, 76(3): 304-313.
[6]
Oberoi RK, Parrish KE, Sio TT, et al. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol, 2016, 18(1): 27-36.
[7]
Ulyte A, Katsaros VK, Liouta E, et al. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients. Neuroradiology, 2016, 58(12): 1197-1208.
[8]
Chen X, Xie T, Fang J, et al. Quantitative in vivo imaging of tissue factor expression in glioma using dynamic contrast-enhanced MRI derived parameters. Eur J Radiol, 2017, 93: 236-242.
[9]
Thomas AA, Arevalo-Perez J, Kaley T, et al. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol, 2015, 125(1): 183-190.
[10]
Larsen VA, Simonsen HJ, Law I, et al. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology, 2013, 55(3): 361-369.
[11]
Choi SH, Jung SC, Kim KW, et al. Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. J Neurooncol, 2016, 128(2): 185-194.
[12]
Yoo RE, Choi SH, Kim TM, et al. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. Eur Radiol, 2017, 27(8): 3156-3166.
[13]
King AD, Chow SK, Yu KH, et al. DCE-MRI for Pre-treatment prediction and post-treatment assessment of treatment response in sites of squamous cell carcinoma in the head and neck. PLoS One, 2015, 10(12): e144770.
[14]
Shukla-Dave A, Lee NY, Jansen JF, et al. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1837-1844.
[15]
Lowe NM, Kershaw LE, Bernstein JM, et al. Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. PLoS One, 2018, 13(3): e194841.
[16]
Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging, 1999, 10(3): 277-285.
[17]
Huang SY, Chen BB, Lu HY, et al. Correlation among DCE-MRI measurements of bone marrow angiogenesis, microvessel density, and extramedullary disease in patients with multiple myeloma. Am J Hematol, 2012, 87(8): 837-839.
[18]
Huang W, Beckett BR, Tudorica A, et al. Evaluation of soft tissue sarcoma response to preoperative chemoradiotherapy using dynamic contrast-enhanced magnetic resonance imaging. Tomography, 2016, 2(4): 308-316.
[19]
Kim JI, Lee IS, Song YS, et al. Short-term follow-up MRI after unplanned resection of malignant soft-tissue tumours; quantitative measurements on dynamic contrast enhanced and diffusion-weighted MR images. Br J Radiol, 2016, 89(1066): 20160302.
[20]
Fujimoto K, Abe T, Muller NL, et al. Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis. Radiology, 2003, 227(3): 786-793.
[21]
Ohno Y, Adachi S, Kono M, et al. Predicting the prognosis of non-small cell lung cancer patient treated with conservative therapy using contrast-enhanced MR imaging. Eur Radiol, 2000, 10(11): 1770-1781.
[22]
Ohno Y, Nogami M, Higashino T, et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy, J Magn Reson Imaging, 2005, 21(6): 775-783.
[23]
Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol, 2016, 26(2): 407-416.
[24]
Chen BB, Hsu CY, Yu CW, et al. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol, 2017, 27(7): 3069-3079.
[25]
Baba S, Isoda T, Maruoka Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med, 2014, 55(5): 736-742.
[26]
Kitajima K, Miyoshi Y, Yamano T, et al. Prognostic value of FDG-PET and DWI in breast cancer. Ann Nucl Med, 2018, 32(1): 44-53.
[27]
Tuncbilek N, Tokatli F, Altaner S, et al. Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients. Eur J Radiol, 2012, 81(5): 863-867.
[28]
Kim JY, Kim SH, Kim YJ, et al. Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers? Magn Reson Imaging, 2015, 33(1): 72-80.
[29]
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med, 2010, 363(20): 1938-1948.
[30]
Park VY, Kim EK, Kim MJ, et al. Perfusion parameters on breast dynamic contrast-enhanced mri are associated with disease-specific survival in patients with triple-negative breast cancer. AJR Am J Roentgenol, 2017, 208(3): 687-694.
[31]
Lund KV, Simonsen TG, Hompland T, et al. Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer. Radiother Oncol, 2015, 115(3): 379-385.
[32]
Yuh WT, Mayr NA, Jarjoura D, et al. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Invest Radiol, 2009, 44(6): 343-350.
[33]
Lund KV, Simonsen TG, Kristensen GB, et al. Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer. Acta Oncol, 2017, 56(5): 675-681.
[34]
Haldorsen IS, Gruner R, Husby JA, et al. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. Eur Radiol, 2013, 23(10): 2916-2925.
[35]
Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol, 2014, 65(6): 1046-1055.
[36]
Singanamalli A, Rusu M, Sparks RE, et al. Identifying in vivo DCE MRI markers associated with microvessel architecture and gleason grades of prostate cancer. J Magn Reson Imaging, 2016, 43(1): 149-158.
[37]
Wu X, Reinikainen P, Kapanen M, et al. Dynamic contrast-enhanced imaging as a prognostic tool in early diagnosis of prostate cancer: correlation with PSA and clinical stage. Contrast Media Mol Imaging, 2018, 2018(2018): 3181258.

PREV Advances in artificial intelligence of cardiovascular imaging
NEXT Study of the relationship between the characteristics of basilar artery plaque with mild stenosis and clinical symptoms based on HR-MRI
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn